Carregando...
 
Esconder menu esquerdo | Tamanho de texto a a a
  • Saad ED Katz A Buyse M. Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials. J Clin Oncol 2010 Mar 1 [Epub ahead of print].
  • Saad ED Katz A Hoff PM Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7-12.
  • Saad ED Mangabeira A Masson AL et al. The geography of clinical cancer research: analysis of abstracts presented at the American Society of Clinical Oncology Annual Meetings. Ann Oncol 2010;21:627-32.
  • Fonseca M Araújo GT Saad ED. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras 2009;55:410-5.
  • Katz A Calabrich A Saad ED. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:2367-8.
  • Katz A Saad ED. CALGB 9633: An underpowered trial with a methodologically questionable conclusion. J Clin Oncol 2009;27:2300-1.
  • Saad ED Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 2009;20:460-4.
  • Saad ED Pinheiro CM Masson AL et al. Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings. Clinics 2008;63:293-6.
  • Brumatti G Yon M Castro FA Bueno-da-Silva AEB Jacysyn JF Brunner T Amarante-Mendes GP. Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide. Exp Cell Res 2008;314:554-63.
  • Carillo BA Beutel A Mirandola DA et al. Differential sympathetic and angiotensinergic responses in rats submitted to low- or high-salt diet. Regul Pept 2007;140:5-11.
  • Katz A Saad ED Porter P Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 2007;8:55-62.
  • Riechelmann RP Tannock IF Wang L Saad ED Taback NA Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600.
  • Machado-Netto MC Lacerda EC Heinke T Maia DC Lowen MS Saad ED. Massive orbital metastasis of hepatocellular carcinoma. Clinics 2006;61:359-62.
  • Riechelmann RP Saad ED. A systematic review on drug interactions in oncology. Cancer Invest 2006;24:704-12.
  • Riechelmann RP Moreira F Smaletz O Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005;56:286-90.
  • Saad ED Hoff PM. Chemotherapy of Metastatic Colorectal Cancer. Curr Treat Options Gastroenterol 2005;8:239-247.
  • Hoff PM Saad ED Pazdur R Wolff R Lassere Y Bogaard KR Abbruzzese JL. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Invest New Drugs 2004;22:307-13.
  • Saad ED Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control 2004;11:32-8.
  • Silva SO Rodrigues MR Ximenes VF Bueno-da-Silva AEB Amarante-Mendes GP Campa A. Neutrophils as a specific target for melatonin and kynuramines effects on cytokine release. J Neuroimmunol 2004;156:146-152. J Neuroimmunol 2004; 156:146-152.
  • Ramos MG Rabelo FL Brumatti G Bueno-da-Silva AEB Amarante-Mendes GP Alvarez-Leite JL. Butyrate increases apoptosis induced by different antineoplastic drugs in monocytic leukemia cells. Chemotherapy 2004;50:221-8
  • Hoff PM Saad ED Ajani JA Lassere Y Wenske C Medgyesy D Dwivedy S Russo M Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003;9:134-42.
  • Rotea W Jr Saad ED. Targeted drugs in oncology: new names new mechanisms new paradigm. Am J Health Syst Pharm 2003;60:1233-43.
  • Saad ED Hoff PM. UFT and oral leucovorin as radiation sensitizers in rectal and other gastrointestinal malignancies. Cancer Invest 2003;21:624-9.
  • Bueno-da-Silva AEB, Brumatti G, Russo FO, Green DR, Amarante-Mendes, GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death and Differ 2003;10:592-8.
  • Abushullaih S Saad ED Munsell M Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002;20:3-10.
  • Saad ED Abbruzzese JL. Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma. Crit Rev Oncol Hematol 2002;41:205-11.
  • Saad ED Kraut EH Hoff PM Moore DF Jr Jones D Pazdur R Abbruzzese JL. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol 2002;25:451-3.
  • Saad ED Machado MC Wajsbrot D Abramoff R Hoff PM Tabacof J Katz A Simon SD Gansl RC. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41.
  • Elasmar SA Saad ED Hoff PM. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. JPN J Clin Oncol 2001;31:172-4.
  • Hoff PM Saad ED Ravandi-Kashani F Czerny E Pazdur R. Phase I trial of i.v. administered tirapazamine plus cyclophosphamide. Anticancer Drugs 2001;12:499-503.
  • Saad ED Hoff PM. Other fluorinated pyrimidines in the treatment of solid tumors. Oncology (Williston Park) 2001;15(Suppl 2):65-8.
  • Hoff PM Janjan N Saad ED Skibber J Crane C Lassere Y Cleary KR Benner S Randolph J Abbruzzese JL Pazdur R. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 2000;18:3529-34.
  • Hoff PM Saad ED Janjan N Skibber J Pazdur R. A phase I study. Preoperative UFT/leucovorin and radiation therapy in rectal cancer. Oncology (Williston Park) 2000;14(Suppl 9):56-8.
  • Saad ED Thomas DA O'Brien S Fuller GN Medeiros LJ Forman A Albitar M Schomer D Kantarjian HM Keating MJ. Progressive multifocal leukoencephalopathy with concurrent Richter's syndrome. Leuk Lymphoma 2000;38:183-90.
  • Saad ED Grunspun H. Medicina baseada em evidências (Evidence-based medicine). Rev Hosp Clin Fac Med Sao Paulo 1996;51:34-6.
  • Mazzantini RP, de Conti A et al. Persistent and remodeling hepatic preneoplastic lesions present differences in cell proliferation and apoptosis, as well as in p53, Bcl-2 and NF-kappaB pathways. J Cell Biochem. 2008 Feb 1;103(2):538-46.
  • de Almeida Vasconcelos Fonseca EM, Chagas CE, Mazzantini RP, Heidor R, Ong TP, Moreno FS. All-trans and 9-cis retinoic acids, retinol and beta-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage. Carcinogenesis. 2005 Nov;26(11):1940-6. Epub 2005 Jun 23.
  • de Moura Espíndola R, Mazzantini RP, Ong TP, de Conti A, Heidor R, Moreno FS. Geranylgeraniol and beta-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-kappaB activation. Carcinogenesis. 2005 Jun;26(6):1091-9. Epub 2005 Feb 17.
  • Mazzantini RP, Miyaji EN, Dias WO, Sakauchi D, Nascimento AL, Raw I, Winter N, Gicquel B, Rappuoli R, Leite LC. Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C. Vaccine. 2004 Jan 26;22(5-6):740-6.

  • Miyaji EN, Mazzantini RP, Dias WO, Nascimento AL, Marcovistz R, Matos DS, Raw I, Winter N, Gicquel B, Rappuoli R, Leite LC. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin.

     Infect Immun. 2001 Feb;69(2):869-74.
  • Nascimento IP, Dias WO, Mazzantini RP, Miyaji EN, Gamberini M, Quintilio W, Gebara VC, Cardoso DF, Ho PL, Raw I, Winter N, Gicquel B, Rappuoli R, Leite LC. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun. 2000 Sep;68(9):4877-83. Erratum in: Infect Immun 2001 Mar;69(3):1976.